Clinical trial • Phase III • Oncology
Clinical trial in Non-small cell lung cancer|EGFR-mutant non-small cell lung cancer
Phase III trial for Non-small cell lung cancer|EGFR-mutant non-small cell lung cancer. 92 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Non-small cell lung cancer|EGFR-mutant non-small cell lung cancer
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 21-06-2024
- First CTIS Authorization Date
- 05-07-2024
Trial design
Phase III trial across 3 sites in Germany, Italy.
- Biomarker Stratified
- True, biomarker: EGFR mutation (EGFR-mutant)
- Target Sample Size
- 92
Recruitment
- Planned Sample Size
- 92
- Recruitment Window Months
- 96
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 52
Germany
- Latest Decision Or Authorization Date
- 05-11-2025
- Number Of Sites
- 2
- Number Of Participants
- 25
Sites
- Site Name
- University Hospital Cologne AöR
- Department Name
- #2001:Klinik I fuer Innere Medizin
- Contact Person Name
- Juergen Wolf
- Contact Person Email
- juergen.wolf@uk-koeln.de
- Site Name
- Universitaetsklinikum Essen AöR
- Department Name
- #2002:Westdeutsches Tumorzentrum
- Contact Person Name
- Martin Schuler
- Contact Person Email
- martin.schuler@uk-essen.de
Italy
- Latest Decision Or Authorization Date
- 10-06-2025
- Number Of Sites
- 1
- Number Of Participants
- 27
Sites
- Site Name
- Azienda Ospedaliero Universitaria Delle Marche
- Department Name
- 4001: Clinica di Oncologia Medica
- Contact Person Name
- Rossana Berardi
- Contact Person Email
- Rossana.Berardi@ospedaliriuniti.marche.it
Sponsor
Primary sponsor
- Full Name
- Novartis Pharma AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)